epilepsy%20(pediatric)
EPILEPSY (PEDIATRIC)
Epileptic seizure is a transient occurrence of signs or symptoms that is due to abnormal excessive or synchronous neuronal activity in the brain.
Epilepsy is a disorder that is characterized by a persistent predisposition of the brain to generate epileptic seizures.
This condition may cause neurobiologic, cognitive, psychological and social disturbances.
It is recommended that all patients having a first seizure be referred to a specialist as soon as possible.

Principles of Therapy

In most clinical settings, seizures are not treated unless ≥2 unprovoked seizures are demonstrated within a 6-month period

Patient Experiences a Single Seizure

  • Detailed history needs to be taken to rule out any previous absence, myoclonic, or partial seizures because patients with undiagnosed epilepsy may present with a single generalized tonic-clonic seizure

Decision to Treat Single Seizure

  • Whether or not to treat a single seizure will be based upon the estimates of risk recurrence which vary
    • Highest recurrence risk rates (up to 90%) are seen in patients who demonstrate epileptic discharges on EEG or have congenital neurological deficits
    • Lowest recurrence risk rates (13-40%) are in patients who experience acute symptomatic seizures (provoked) or those with a normal EEG and no identifiable cause for seizure
  • Treatment with anticonvulsants can reduce the risk of recurrence by half
    • Early treatment has not shown to alter the prognosis of epilepsy
  • Consultation with epilepsy specialist will be needed to decide whether or not to treat a single seizure

Single Generalized Tonic-Clonic Seizure

  • Patient could be given treatment with anticonvulsant if:
    • History of previous myoclonic, absence or focalseizures
    • EEG shows unquestionable epileptic discharges
    • Structural abnormalities are present in brain imaging
    • Patient has congenital neurological deficit
    • Patient decides the risk of recurrence is not acceptable

Pharmacotherapy

Anticonvulsants (First-Line Anticonvulsants)

Choice of anticonvulsant drugs will be based on their indications, adverse effects and interaction profiles

Carbamazepine

  • Used to treat focal to bilateral tonic-clonic seizure and primary generalized tonic-clonic seizures
  • Also used as first-line treatment for patients with benign epilepsy associated with centrotemporal spikes, Panayiotopoulos syndrome, or late-onset childhood occipital epilepsy (Gastaut type)
  • Should be avoided in absence, myoclonic, tonic and atonic seizures
  • Classification: Dibenzazepine derivative

Ethosuximide

  • Used as first-line therapy to treat absence seizures
  • Classification: Succinimide compound

Lamotrigine

  • Used as first-line therapy for focal to bilateral tonic-clonic seizure, and primary generalized tonic-clonic, and absence seizures
  • Used to treat  focal to bilateral tonic-clonic seizure and primary generalized tonic-clonic seizures
  • Also used as adjunctive treatment for generalized tonic or atonic seizure, Lennox-Gastaut syndrome, and as tertiary therapy for myoclonic seizures
  • May also be used as 1st-line treatment for idiopathic generalized onset epilepsy if Valproate is ineffective or not tolerated
  • Classification: Phenyltriazine compound

Levetiracetam

  • Used as first-line therapy for focal to bilateral tonic-clonic seizure, primary generalized myoclonic seizures, idiopathic generalized epilepsy, and juvenile myoclonic epilepsy
  • Also used as adjunctive treatment for primary generalized tonic-clonic seizures, and tertiary therapy for absence seizures
  • Also recommended as 2nd-line therapy for patients with benign epilepsy associated with centrotemporal spikes, Panayiotopoulos syndrome, or late-onset childhood occipital epilepsy (Gastaut type) if treatment failure with Carbamazepine or Lamotrigine occurs
  • Classification: Analogue of Piracetam which is a nootropic

Oxcarbazepine

  • Used as 1st-line monotherapy for focal to bilateral tonic-clonic seizure, and for primary generalized tonic-clonic seizures
    • At 2,400 mg/day, was shown to be effective in monotherapy for refractory focal epilepsy
  • Recommended as adjunctive treatment for patients with benign epilepsy associated with centrotemporal spikes, Panayiotopoulos syndrome, or late-onset childhood occipital epilepsy (Gastaut type)
  • Similar efficacy to Carbamazepine
    • Additional benefits were seen when Oxcarbazepine was added to Carbamazepine therapy
  • Better tolerated than Carbamazepine, fewer drug interactions and less physician monitoring is required
  • Should be avoided in absence and myoclonic seizures
  • Classification: 10-keto analogue of Carbamazepine

Topiramate

  • Used as first-line monotherapy in patients with generalized myoclonic seizures, in newly diagnosed patients with epilepsy, or conversion to monotherapy, or as adjunctive treatment for focal to bilateral tonic-clonic seizure, generalized tonic-clonic seizures, and Lennox-Gastaut syndrome
    • Also used as tertiary treatment for patients with generalized absence and tonic or atonic seizures
    • In some countries, Topiramate is only approved as adjunctive treatment
  • May also be used as 1st-line treatment for myoclonic epilepsy of infancy, juvenile myoclonic epilepsy, and patients with Dravet syndrome
  • Classification: Sulfamate-substituted monosaccharide

Valproate (Divalproex, Sodium Valproate, Valproic Acid)

  • Used as 1st-line therapy to treat focal to bilateral tonic-clonic seizure, all generalized seizures, and idiopathic generalized epilepsy
  • May also be used as 1st-line therapy for juvenile myoclonic epilepsy, Dravet syndrome, and Lennox-Gastaut syndrome
  • Reasonable evidence supports the use of Valproic acid along with Lamotrigine and Ethosuximide for childhood absence epilepsy
  • Important adverse effect is weight gain
  • Classification: Carboxylic acid derivative

Anticonvulsants (Adjunctive/Tertiary Anticonvulsants)

  • Recommended for patients who have not benefited from treatment with first-line antiepileptic medications or for whom these drugs are not suitable (eg poor tolerance, contraindications to first-line drugs, etc.)

Eslicarbazepine acetate

  • Used as tertiary treatment for refractory focal to bilateral tonic-clonic seizure if adjunctive therapies are ineffective or not tolerated
  • Classification: Carboxamide derivative

Felbamate

  • Used as adjunctive treatment for seizure associated with Lennox-Gastaut syndrome

Gabapentin

  • Used as adjunctive treatment for focal to bilateral tonic-clonic seizure
  • Should be avoided in absence and myoclonic seizures
  • Classification: Gamma-aminobutyric acid (GABA) analogue

Lacosamide

  • Used as tertiary treatment for refractory focal to bilateral tonic-clonic seizure

Phenobarbital (Phenobarbitone)

  • Treats focal onset seizures, generalized tonic-clonic, tonic and atonic seizures, and status epilepticus
  • Consider as a last-line agent; May have adverse effect on patient’s cognition
  • Classification: Barbiturate

Phenytoin

  • Used to treat focal onset seizures, generalized tonic-clonic seizures and status epilepticus
    • Valproate and Carbamazepine may be preferred since they tend to have fewer adverse effects
  • Classification: Hydantoin compound
  • Associated with gum hypertrophy

Pregabalin

  • Used as tertiary treatment for patients with refractory focal onset seizures
  • Classification: Gamma-aminobutyric acid (GABA) analogue

Primidone

  • Used as tertiary treatment for focal onset seizures, and generalized tonic-clonic seizures
  • Classification: Barbiturate, related to Phenobarbital and partially metabolized to Phenobarbital

Rufinamide

  • Used as tertiary treatment for generalized tonic or atonic seizures, and adjunctive therapy for Lennox-Gastaut syndrome in children ≥4 years old
  • Classification: Carboxamide derivative

Tiagabine

  • Used as tertiary therapy for focal to bilateral tonic-clonic seizure
  • Should be avoided in generalized tonic-clonic, absence and myoclonic seizures
  • Classification: Nipecotic acid derivative

Vigabatrin

  • Used as tertiary therapy for refractory focal to bilateral tonic-clonic seizure
    • Should be reserved for patients not adequately controlled by other agents
  • First-line treatment for patients with infantile spasms secondary to tuberous sclerosis
    • May also be offered as 1st-line therapy for non-tuberous sclerosis and infantile spasms
  • Should be avoided in generalized tonic-clonic, absence and myoclonic seizures
  • Associated with visual field impairment in adults but few data exist in pediatric patients
  • Classification: GABA analogue

Zonisamide

  • Used as tertiary treatment for focal to bilateral tonic-clonic seizures, generalized absence and myoclonic seizures
  • Also used as adjunctive treatment for juvenile myoclonic epilepsy
  • Actions: Benzisoxazole derivative

Benzodiazepines

Use of benzodiazepines may be limited by development of tolerance and sedation; other antiepileptics are usually preferred

Clobazam

  • Recommended as adjunctive treatment for patients with focal to bilateral tonic-clonic seizures, benign epilepsy associated with centrotemporal spikes, Panayiotopoulos syndrome, or late-onset childhood occipital epilepsy (Gastaut type), and juvenile myoclonic epilepsy
  • Also used as tertiary treatment for patients with generalized absence and myoclonic seizures
  • Actions: Long-acting benzodiazepine with similar actions to Diazepam

Clonazepam

  • Used as an adjunctive treatment for generalized absence seizures, and as an alternative to other antiepileptics in status epilepticus
  • Also used as tertiary treatment for focal to bilateral tonic-clonic seizure, and generalized myoclonic seizures
  • Actions: Long-acting benzodiazepine with similar actions to Diazepam

Diazepam

  • Used as an adjunctive treatment for all types of seizures and status epilepticus
  • Actions: Long-acting benzodiazepine which acts by enhancing GABA activity in the brain

Lorazepam

  • Used as 1st-line agent in the treatment of status epilepticus
    • Advantageous to Diazepam in status epilepticus because it has a longer duration of action
    • Disadvantage: Parenteral form requires refrigeration
  • Actions: Long-acting benzodiazepine with similar actions to Diazepam

Midazolam

  • Used to treat status epilepticus resistant to treatment by Diazepam, Lorazepam and Phenytoin
  • Actions: Short-acting benzodiazepine with similar actions to Diazepam

Nitrazepam

  • Used as tertiary treatment for patients with generalized myoclonic seizures, and to treat epilepsy especially infantile spasm
  • Actions: Intermediate-acting benzodiazepine with similar actions to Diazepam

Pinazepam

  • Used as adjunctive treatment for epilepsy
  • Actions: Long-acting benzodiazepine with similar actions to Diazepam

Others

Acetazolamide

  • Used as adjunctive treatment for refractory focal to bilateral tonic-clonic seizure, atypical absence, tonic, atonic and myoclonic seizures resistant to conventional treatment
  • Actions: Inhibits carbonic anhydrase in glial cells in central nervous system (CNS)

Flunarizine

  • Used as adjunctive treatment for focal seizures resistant to conventional treatment
  • Actions: Difluorinated derivative of Cinnarizine, antihistamine, sedative and Calcium antagonist activity

 Paraldehyde

  • Used to treat status epilepticus resistant to conventional treatment
    • Use is limited by the hazards associated with its administration
  • Actions: Sedative and hypnotic with antiepileptic effects

Piracetam

  • Used as tertiary treatment for patients with generalized myoclonic seizures
  • Actions: Nootropic with CNS protective properties against hypoxia

Prednisolone

  • Used as 1st-line treatment for patients with infantile spasms without tuberous sclerosis

Propofol

  • As an anesthetic, it is used in conjunction with assisted ventilation to control refractory status epilepticus
  • Actions: Short-acting anesthetic

Tetracosactide

  • Also recommended for patients with non-tuberous sclerosis-caused infantile spasms

Combination Therapy

  • Consider combination therapy if:
    • Patient has substantial seizure control with 1st-line agent but still experiences seizures at maximum dose
  • Drugs used in combination should be matched to patient’s seizure type
  • Max 3 drugs can be combined; better if only 2 are used
  • Combination therapy should be administered as such:
    • Administer the best monotherapy option at optimal dose with no side effects
    • Administer the subsequent drugs after that, increase dose of each slowly to obtain max response with minimal toxicity

Non-Pharmacological Therapy

Vagus Nerve Stimulation

  • Adjunctive intervention to reduce frequency of seizures in patients with focal to bilateral tonic-clonic or generalized onset seizures refractory to anticonvulsants
  • Optional treatment for patients with contraindications for surgery

Nutrition

  • A ketogenic diet may help in the management of pediatric patients
    • Studies have shown marked reduction in seizure frequency in children on high fat, low carbohydrate controlled protein (ketogenic) diet

Psychological Interventions

  • Eg relaxation techniques, cognitive behavior therapy
  • May be helpful in pediatric patients with focal epilepsy

Treatment Maintenance

  • Routine level monitoring of anti-epileptic drug is not recommended in patients but may be considered
  • Continue treatment for 2-5 years
  • If patient is seizure-free after 2-5 years, drug withdrawal may be considered based on patient preference, seizure type and history
  • Withdraw treatment gradually, over a few months, to prevent recurrent seizures
  • Patients already receiving anticonvulsant drugs who present with an unexplained seizure should have an anticonvulsant level checked
  • Withdraw 1 drug at a time in combination therapy
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
18 Aug 2018
Despite the absence of a substance use problem, regular cannabis use is associated with psychosocial impairment among adolescents and young adults, a study suggests. On the other hand, regular users with cannabis use disorder appear to exhibit high psychiatric comorbidity and more severe psychosocial impairment.
07 Sep 2018
Children with Down syndrome appear to have an elevated risk of developing severe respiratory syncytial virus (RSV) infection, a study has found.
21 Mar 2018
During the Kuala Lumpur International Neonatology Conference held in conjunction with the World Prematurity Day 2017, Dato Dr Musa Mohd Nordin spoke on the importance of immunizing children with the diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b (DTaP-IPV-Hib) vaccine. He highlighted the role of Hexaxim® as a fully liquid, ready-to-use, 6-in-1 (including hepatitis B) vaccine for the primary and booster vaccinations of infants and toddlers. Meanwhile, Dr Yong Junina Fadzil discussed the benefits of quadrivalent influenza vaccines (QIVs) in providing children with broader protection against influenza B viruses.
Jairia Dela Cruz, 01 Sep 2018
Tight glycaemic control does not yield significant short-term survival gains and risk reductions for infections when compared with a conventional glucose-lowering strategy in critically ill patients in the paediatric intensive care unit, according to a meta-analysis.